1
|
Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm DM, Hanusch C, Solbach C, Heinrich G, Hartkopf AD, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). ESMO Open 2024; 9:103009. [PMID: 38663168 PMCID: PMC11061217 DOI: 10.1016/j.esmoop.2024.103009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Accepted: 03/23/2024] [Indexed: 05/04/2024] Open
Abstract
BACKGROUND The GENEVIEVE study, comparing neoadjuvant cabazitaxel versus paclitaxel in triple-negative breast cancer (TNBC) and luminal B/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC), previously reported significant differences in pathological complete response (pCR) rates. Effects on long-term outcome are unknown. PATIENTS AND METHODS GENEVIEVE randomized patients with cT2-3, any cN or cT1, cN+/pNSLN+, centrally confirmed TNBC or luminal B/HER2-negative BC (latter defined as estrogen/progesterone receptor-positive and >14% Ki-67-stained cells) to receive either cabazitaxel 25 mg/m2 q3w for four cycles or paclitaxel 80 mg/m2 weekly for 12 weeks. Anthracycline-containing chemotherapy was allowed in case of histologically proven invasive residuals as neoadjuvant treatment or after surgery as adjuvant treatment. Here we report the secondary endpoints invasive disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival (OS). RESULTS Of the 333 patients randomized, 74.7% and 83.2% completed treatment in the cabazitaxel and paclitaxel arms, respectively. After a median follow-up of 89.3 months (interquartile range 68.8-97.3 months), 80 iDFS events (43 after cabazitaxel and 37 after paclitaxel) and 47 deaths (23 after cabazitaxel and 24 after paclitaxel) were reported. IDFS rates were not significantly different between the cabazitaxel and paclitaxel arms after a 3-year (83.6% versus 85.0%) and 5-year follow-up (76.2% versus 78.3%) [hazard ratio (HR) = 1.27, 95% confidence interval 0.82-1.96, P = 0.294], respectively. DDFS rates at 3 years (88.6% versus 87.8%) and 5 years (82.1% versus 82.8%) for cabazitaxel and paclitaxel were comparable (HR = 1.15, P = 0.573). Similarly, OS rates at 3 years (91.6% versus 91.8%) and 5 years (89.2% versus 86.8%) showed no significant differences (HR = 1.05, P = 0.872). Subgroup analysis for TNBC and luminal B/HER2-negative BCs indicated no significant variations in 3- or 5-year iDFS, DDFS, or OS. CONCLUSIONS The significant differences in pCR rates observed in both treatment arms did not significantly impact long-term outcomes for patients treated with cabazitaxel versus paclitaxel in the GENEVIEVE trial.
Collapse
Affiliation(s)
- P Meyer-Wilmes
- Klinik für Gynäkologie und Geburtsmedizin, Uniklinik Aachen, Aachen, Germany
| | - J Huober
- Department of Interdisciplinary Medical Services, University Hospital Ulm & Cantonal Hospital St. Gallen, Breast Center, St. Gallen, Switzerland
| | - M Untch
- Helios Kliniken Berlin-Buch, Berlin
| | - J-U Blohmer
- Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Berlin
| | | | - C Denkert
- Institut für Pathologie, Philipps-University Marburg and University Hospital Marburg (UKGM)-Universitätsklinikum Marburg, Marburg
| | - P Klare
- MediOnko-Institut GbR Berlin, Berlin
| | - T Link
- Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden
| | - K Rhiem
- Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln
| | - C Bayer
- Universitätsklinikum Erlangen, Erlangen
| | - M Reinisch
- Department of Gynecology with Breast Center, Evang. Kliniken Essen-Mitte, Charité - Universitätsmedizin Berlin, Berlin
| | - V Bjelic-Radisic
- Breast Unit, University Hospital Helios, University Witten Herdecke, Wuppertal
| | - D M Zahm
- SRH Waldklinikum Gera GmbH, Gera
| | | | - C Solbach
- Department of Gynecology and Obstetrics, Goethe University Frankfurt, University Hospital, Frankfurt
| | - G Heinrich
- Schwerpunktpraxis der Gynäkologie und Onkologie Fürstenwalde, Klinikum Offenbach
| | - A D Hartkopf
- AGO Study Group and Department of Women's Health, University Hospital Tübingen, Tübingen
| | - A Schneeweiss
- Nationales Centrum für Tumorerkrankungen, Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg
| | | | - N Filmann
- German Breast Group, Neu-Isenburg, Germany
| | | | | | - E Stickeler
- Klinik für Gynäkologie und Geburtsmedizin, Uniklinik Aachen, Aachen, Germany
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany.
| |
Collapse
|
2
|
Dannehl D, Jakob D, Mergel F, Estler A, Engler T, Volmer L, Frevert ML, Matovina S, Englisch A, Tegeler CM, Rohner A, Seller A, Hahn M, Pfister K, Fink A, Popp I, Lorenz S, Tabatabai G, Juhasz-Böss I, Janni W, Brucker S, Taran FA, Hartkopf A, Schäffler H. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis. ESMO Open 2024; 9:102995. [PMID: 38636292 PMCID: PMC11039313 DOI: 10.1016/j.esmoop.2024.102995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 02/22/2024] [Accepted: 03/11/2024] [Indexed: 04/20/2024] Open
Abstract
BACKGROUND Fifteen to thirty percent of all patients with metastatic breast cancer (MBC) develop brain metastases (BCBMs). Recently, the antibody-drug conjugates (ADCs) sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have shown to be highly effective in the treatment of MBC. However, there are only limited data whether these macromolecules are also effective in patients with BCBMs. We therefore aimed to examine the efficacy of SG and T-DXd in patients with stable and active BCBMs in a multicenter real-world analysis. PATIENTS AND METHODS Female patients with stable or active BCBMs who were treated with either SG or T-DXd at three breast centers in Germany before 30 June 2023 were included. As per local clinical praxis, chemotherapy efficacy was evaluated by whole-body computed tomography and cranial magnetic resonance imaging at baseline and at least every 3 months according to local standards. Growth dynamics of BCBMs were assessed by board-certified neuroradiologists. RESULTS Of 26 patients, with a median of 2.5 prior therapy lines in the metastatic setting (range 2-15), 12 (43%) and 16 (57%) patients received SG and T-DXd, respectively. Out of the 12 patients who received SG, 2 (17%) were subsequently treated with T-DXd. Five out of 12 (42%) and 5 out of 16 (31%) patients treated with SG and T-DXd, respectively, had active BCBMs at treatment initiation. The intracranial disease control rate was 42% [95% confidence interval (CI) 13% to 71%] for patients treated with SG and 88% (95% CI 72% to 100%) for patients treated with T-DXd. After a median follow-up of 12.7 months, median intracranial progression-free survival was 2.7 months (95% CI 1.6-10.5 months) for SG and 11.2 months (95% CI 7.5-23.7 months) for T-DXd. CONCLUSIONS SG and T-DXd showed promising clinical activity in both stable and active BCBMs. Further prospective clinical studies designed to investigate the efficacy of modern ADCs on active and stable BCBMs are urgently needed.
Collapse
Affiliation(s)
- D Dannehl
- Department of Women's Health, Tuebingen University, Tuebingen.
| | - D Jakob
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg
| | - F Mergel
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - A Estler
- Department of Radiology, Section for Diagnostic and Interventional Neuroradiology, Tuebingen
| | - T Engler
- Department of Women's Health, Tuebingen University, Tuebingen
| | - L Volmer
- Department of Women's Health, Tuebingen University, Tuebingen
| | - M-L Frevert
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg
| | - S Matovina
- Department of Women's Health, Tuebingen University, Tuebingen
| | - A Englisch
- Department of Women's Health, Tuebingen University, Tuebingen
| | - C M Tegeler
- Department of Women's Health, Tuebingen University, Tuebingen
| | - A Rohner
- Department of Women's Health, Tuebingen University, Tuebingen
| | - A Seller
- Department of Women's Health, Tuebingen University, Tuebingen
| | - M Hahn
- Department of Women's Health, Tuebingen University, Tuebingen
| | - K Pfister
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - A Fink
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - I Popp
- Department of Radiation Oncology, University Medical Center Freiburg, Freiburg
| | - S Lorenz
- Department of Radiology, Ulm University, Ulm
| | - G Tabatabai
- Center for Neurooncology, Comprehensive Cancer Center, Tuebingen University, Tuebingen, Germany
| | - I Juhasz-Böss
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg
| | - W Janni
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - S Brucker
- Department of Women's Health, Tuebingen University, Tuebingen
| | - F-A Taran
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg
| | - A Hartkopf
- Department of Women's Health, Tuebingen University, Tuebingen; Department of Gynecology and Obstetrics, Ulm University, Ulm
| | - H Schäffler
- Department of Gynecology and Obstetrics, Ulm University, Ulm
| |
Collapse
|
3
|
Frevert ML, Dannehl D, Jansen L, Hermann S, Schäffler H, Huwer S, Janni W, Juhasz-Böss I, Hartkopf AD, Taran FA. Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry. Arch Gynecol Obstet 2024:10.1007/s00404-024-07405-5. [PMID: 38472501 DOI: 10.1007/s00404-024-07405-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Accepted: 01/28/2024] [Indexed: 03/14/2024]
Abstract
BACKGROUND Following the positive iDFS and OS results of the phase III clinical trials monarchE, NATALEE and OlympiA, new oral anticancer agents (the CDK4/6 inhibitors abemaciclib, ribociclib as well as the PARP inhibitor olaparib) have recently been introduced into the treatment of high-risk early breast cancer (eBC). However, only few male patients were included in these trials (0.4%, 0.6% and 0.3%, respectively). The objective of this real-world analysis was to determine the proportion of male patients with eBC fulfilling the clinical high-risk criteria of above-mentioned trials. PATIENTS AND METHODS We conducted a data inquiry and analysis with the Cancer Registry of Baden-Württemberg of men with breast cancer diagnosed between January 1, 2015 and December 31, 2021. Men with eBC were identified and the number of patients at clinical high-risk according to the inclusion criteria of monarchE, NATALEE and OlympiA was assessed. RESULTS Of 397 men with eBC, 354 (89.1%) had a HR + /Her2- and 4 (1.0%) a triple-negative subtype. 84 patients (21.2%) met the clinical high-risk criteria according to the monarchE, 189 (47.6%) those according to the NATALEE and 50 (12.6%) those according to the OlympiA trial. CONCLUSION In a large real-world sample, more men with eBC are at clinical high risk according to the inclusion criteria of monarchE, NATALEE and OlympiA than would be expected in women. This is most likely due to more advanced stages at initial diagnosis in men. To evaluate whether CDK4/6 and PARP inhibitors improve prognosis also in men should be the topic of future real- world analyses.
Collapse
Affiliation(s)
- M L Frevert
- Department of Obstetrics and Gynecology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
| | - D Dannehl
- Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany
| | - L Jansen
- Epidemiological Cancer Registry of Baden-Württemberg, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - S Hermann
- Epidemiological Cancer Registry of Baden-Württemberg, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - H Schäffler
- Department of Obstetrics and Gynecology, University Clinic Ulm, Faculty of Medicine, University of Ulm, Ulm, Germany
| | - S Huwer
- Department of Obstetrics and Gynecology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany
| | - W Janni
- Department of Obstetrics and Gynecology, University Clinic Ulm, Faculty of Medicine, University of Ulm, Ulm, Germany
| | - I Juhasz-Böss
- Department of Obstetrics and Gynecology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany
| | - A D Hartkopf
- Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany
| | - F-A Taran
- Department of Obstetrics and Gynecology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany
| |
Collapse
|
4
|
Dannehl D, Dijkstra T, Gutsfeld R, Au AV, Volmer L, Engler T, Hahn M, Hawighorst-Knapstein S, Chaudhuri A, Wallwiener M, Bauer A, Brucker S, Wallwiener S, Hartkopf A. P010 Retrospective modeling of adherence to endocrine therapy in early breast cancer using real-world claims data. Breast 2023. [DOI: 10.1016/s0960-9776(23)00129-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
5
|
Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021; 6:100299. [PMID: 34839105 PMCID: PMC8637493 DOI: 10.1016/j.esmoop.2021.100299] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 09/25/2021] [Accepted: 10/11/2021] [Indexed: 10/31/2022] Open
Abstract
BACKGROUND Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive CTCs are found in some patients with HER2-negative tumors. PATIENTS AND METHODS Patients with HER2-negative MBC were screened for participation in DETECT III and IV trials before the initiation of a new line of therapy. Blood samples were analyzed using CELLSEARCH. CTCs were labeled with an anti-HER2 antibody and classified according to staining intensity (negative, weak, moderate, or strong staining). RESULTS Screening blood samples were analyzed in 1933 patients with HER2-negative MBC. As many as 1217 out of the 1933 screened patients (63.0%) had ≥1 CTC per 7.5 ml blood; ≥5 CTCs were detected in 735 patients (38.0%; range 1-35 078 CTCs, median 8 CTCs). HER2 status of CTCs was assessed in 1159 CTC-positive patients; ≥1 CTC with strong HER2 staining was found in 174 (15.0%) patients. The proportion of CTCs with strong HER2 staining among all CTCs of an individual patient ranged between 0.06% and 100% (mean 15.8%). Patients with estrogen receptor (ER)- and progesterone receptor (PR)-positive tumors were more likely to harbor ≥1 CTC with strong HER2 staining. CTC status was significantly associated with overall survival (OS). Detection of ≥1 CTC with strong HER2 staining was associated with shorter OS [9.7 (7.1-12.3) versus 16.5 (14.9-18.1) months in patients with CTCs with negative-to-moderate HER2 staining only, P = 0.013]. In multivariate analysis, age, ER status, PR status, Eastern Cooperative Oncology Group performance status, therapy line, and CTC status independently predicted OS. CONCLUSION CTC detection in patients with HER2-negative disease is a strong prognostic factor. Presence of ≥1 CTC with strong HER2 staining was associated with shorter OS, supporting a biological role of HER2 expression on CTCs.
Collapse
Affiliation(s)
- V Müller
- Department of Gynecology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
| | - M Banys-Paluchowski
- Gynecology and Obstetrics Department, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Medical Faculty, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany
| | - T W P Friedl
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - P A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - A Schneeweiss
- Division Gynecologic Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
| | - A Hartkopf
- Department of Gynecology and Obstetrics, University Hospital Tübingen, Tübingen, Germany
| | - D Wallwiener
- Department of Gynecology and Obstetrics, University Hospital Tübingen, Tübingen, Germany
| | - B Rack
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - F Meier-Stiegen
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
| | - J Huober
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - M Rübner
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - O Hoffmann
- Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
| | - L Müller
- OnkologieUnterEms, Leer, Germany
| | - W Janni
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - P Wimberger
- Department of Gynecology and Obstetrics, University Hospital Carl Gustav Carus Dresden, TU Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germany
| | - B Jäger
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
| | - K Pantel
- Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - S Riethdorf
- Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - N Harbeck
- Breast Center, Department of Gynecology and Obstetrics and CCC Munich, LMU University Hospital, Munich, Germany
| | - T Fehm
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
| |
Collapse
|
6
|
Asperger H, Cieslik JP, Alberter B, Köstler C, Polzer B, Müller V, Pantel K, Riethdorf S, Koch A, Hartkopf A, Wiesmüller L, Janni W, Schochter F, Franken A, Niederacher D, Fehm T, Neubauer H. ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processing. Transl Oncol 2021; 14:101132. [PMID: 34051621 PMCID: PMC8176360 DOI: 10.1016/j.tranon.2021.101132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Accepted: 05/19/2021] [Indexed: 12/05/2022] Open
Abstract
ViBiBa is an open-source sample banking tool. ViBiBa was purpose built for liquid biopsy specimen. ViBiBa allows for decentralized storage while promoting collaboration. ViBiBa's plugin support requires no change in existing data structures. ViBiBa empowers translational research projects and cohort formation.
Background Liquid Biopsy (LB) in the form of e.g., circulating tumor cells (CTCs) is a promising non-invasive approach to support current therapeutic cancer management. However, the proof of clinical utility of CTCs in informing therapeutic decision-making for e.g., breast cancer in clinical trials and associated translational research projects is facing the issues of low CTC positivity rates and low CTC numbers – even in the metastasized situation. To compensate for this dilemma, clinical CTC trials are designed as large multicenter endeavors with decentralized sample collection, processing and storage of products, making data management highly important to enable high-quality translational CTC research. Aim In the DETECT clinical CTC trials we aimed at developing a custom-made, browser-based virtual database to harmonize and organize both decentralized processing and storage of LB specimens and to enable the collection of clinically meaningful LB sample. Methods ViBiBa processes data from various sources, harmonizes the data and creates an easily searchable multilayered database. Results An open-source virtual bio-banking web-application termed ViBiBa was created, which automatically processes data from multiple non-standardized sources. These data are automatically checked and merged into one centralized databank and are providing the opportunity to extract clinically relevant patient cohorts and CTC sample collections. Summary ViBiBa, which is a highly flexible tool that allows for decentralized sample storage of liquid biopsy specimens, facilitates a solution which promotes collaboration in a user-friendly, federalist and highly structured way. The source code is available under the MIT license from https://vibiba.com or https://github.com/asperciesl/ViBiBa
Collapse
Affiliation(s)
- H Asperger
- Department of Obstetrics and Gynecology, University Hospital Duesseldorf, Moorenstraße 5, Düsseldorf, Germany
| | - J-P Cieslik
- Department of Obstetrics and Gynecology, University Hospital Duesseldorf, Moorenstraße 5, Düsseldorf, Germany
| | - B Alberter
- Division of Personalized Tumor Therapy, Fraunhofer ITEM, Germany, Am Biopark 9, Regensburg, Germany
| | - C Köstler
- Division of Personalized Tumor Therapy, Fraunhofer ITEM, Germany, Am Biopark 9, Regensburg, Germany
| | - B Polzer
- Division of Personalized Tumor Therapy, Fraunhofer ITEM, Germany, Am Biopark 9, Regensburg, Germany
| | - V Müller
- Department of Obstetrics and Gynecology, University Hospital Hamburg-Eppendorf, Germany, Martinistraße 52, Hamburg, Germany
| | - K Pantel
- Department of Tumor Biology, University Hospital Hamburg-Eppendorf, Germany, Martinistraße 52, Hamburg, Germany
| | - S Riethdorf
- Department of Tumor Biology, University Hospital Hamburg-Eppendorf, Germany, Martinistraße 52, Hamburg, Germany
| | - A Koch
- Department of Obstetrics and Gynecology, University of Tübingen, Germany, Calwerstraße 7, Tübingen, Germany
| | - A Hartkopf
- Department of Obstetrics and Gynecology, University of Tübingen, Germany, Calwerstraße 7, Tübingen, Germany
| | - L Wiesmüller
- Department of Obstetrics and Gynecology, University Hospital Ulm, Germany, Albert-Einstein-Allee 23, Ulm, Germany
| | - W Janni
- Department of Obstetrics and Gynecology, University Hospital Ulm, Germany, Albert-Einstein-Allee 23, Ulm, Germany
| | - F Schochter
- Department of Obstetrics and Gynecology, University Hospital Ulm, Germany, Albert-Einstein-Allee 23, Ulm, Germany
| | - A Franken
- Department of Obstetrics and Gynecology, University Hospital Duesseldorf, Moorenstraße 5, Düsseldorf, Germany
| | - D Niederacher
- Department of Obstetrics and Gynecology, University Hospital Duesseldorf, Moorenstraße 5, Düsseldorf, Germany
| | - T Fehm
- Department of Obstetrics and Gynecology, University Hospital Duesseldorf, Moorenstraße 5, Düsseldorf, Germany
| | - H Neubauer
- Department of Obstetrics and Gynecology, University Hospital Duesseldorf, Moorenstraße 5, Düsseldorf, Germany.
| |
Collapse
|
7
|
Boeer B, Schneider J, Schoenfisch B, Röhm C, Paepke S, Oberlechner E, Ohlinger R, Hartkopf A, Brucker SY, Hahn M, Marx M. Lysine-urethane-based tissue adhesion for mastectomy-an approach to reducing the seroma rate? Arch Gynecol Obstet 2020; 303:181-188. [PMID: 33146769 PMCID: PMC7854407 DOI: 10.1007/s00404-020-05801-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 09/16/2020] [Indexed: 11/05/2022]
Abstract
Purpose Postoperative seromas are a problem in the surgical treatment of breast cancer. The aim of the study was to evaluate whether the lysine-urethane-based tissue adhesive TissuGlu® without drainage is equal/ non-inferior to standard mastecomy with drainage. Methods The study was designed as a prospective, randomized, multicentre non-inferiority study comparing the use of TissuGlu® without drainage with standard wound care with a drain insertion in ablative breast procedures. The number of clinical interventions, quality of life and wound complications were followed-up for 90 days in both groups. Results Although the statistical power was not reached, twice as many clinical interventions were performed in the TissuGlu® group than in the drainage group, especially aspirations of clinically relevant seromas (p = 0.014). The TissuGlu® group produced overall less wound fluid, but developed a clinically relevant seroma (100% vs. 63%) which made an intervention necessary. Less hospitalisation time was observed in the TissuGlu® group, but the complication rate was higher. There was no significant difference in regards to postoperative pain. In summary the non-inferiority of TissuGlu® compared to standard drainage couldn’t be reached. Discussion The present evaluation shows no advantage of the tissue adhesive TissuGlu® in terms of seroma formation and frequency of intervention compared to a standard drainage for mastectomies, but the shorter inpatient stay certainly has a positive effect on the quality of life.
Collapse
Affiliation(s)
- B Boeer
- Department of Women's Health, University Hospital of Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany.
| | - J Schneider
- Department of Urology, Klinikum Am Steinenberg, Reutlingen, Germany
| | - B Schoenfisch
- Research Institute for Women's Health, University of Tuebingen, Tuebingen, Germany
| | - C Röhm
- Department of Women's Health, University Hospital of Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany
| | - S Paepke
- Department of Obstetrics and Gynaecology, Technical University of Munich, Munich, Germany
| | - E Oberlechner
- Department of Women's Health, University Hospital of Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany
| | - R Ohlinger
- Department of Gynaecology and Obstetrics, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany
| | - A Hartkopf
- Department of Women's Health, University Hospital of Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany
| | - S Y Brucker
- Department of Women's Health, University Hospital of Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany
| | - M Hahn
- Department of Women's Health, University Hospital of Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany
| | - M Marx
- Department of Plastic, Reconstructive and Breast Surgery, Elblandklinikum Radebeul, Radebeul, Germany
| |
Collapse
|
8
|
Anderle N, Ruoff F, Koch A, Hartkopf A, Brucker S, Templin M, Schmees C. Project PRIMO – Combining Patient Derived Breast Cancer Microtumors and DigiWest protein signaling pathway profiling for therapeutic response prediction. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30721-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Gürgan S, Gruber I, Fugunt R, Sandru M, Helms G, Röhm C, Böer B, Hoopmann U, Hartkopf A, Hahn M. Das seltene Metastasierungsort: Intramammäre und cutane Metastasen des siegelringzelliges Magenkarzinoms. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Gürgan
- Universitätsfrauenklinik Tübingen
| | - I Gruber
- Universitätsfrauenklinik Tübingen
| | - R Fugunt
- Universitätsfrauenklinik Tübingen
| | - M Sandru
- Universitätsfrauenklinik Tübingen
| | - G Helms
- Universitätsfrauenklinik Tübingen
| | - C Röhm
- Universitätsfrauenklinik Tübingen
| | - B Böer
- Universitätsfrauenklinik Tübingen
| | | | | | - M Hahn
- Universitätsfrauenklinik Tübingen
| |
Collapse
|
10
|
Schlammerl K, Engler T, Kölle A, Kommoss S, Brucker SY, Hartkopf A. Komplettremission von 10cm großen inguinalen Lymphknotenmetastasen eines rasch-progredienten metastasierten Endometriumkarzinoms unter Immuntherapie mit Pembrolizumab in Kombination mit Paclitaxel. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- K Schlammerl
- Universitätsfrauenklinik Tübingen, Department für Frauengesundheit
| | - T Engler
- Universitätsfrauenklinik Tübingen, Department für Frauengesundheit
| | - A Kölle
- Universitätsfrauenklinik Tübingen, Department für Frauengesundheit
| | - S Kommoss
- Universitätsfrauenklinik Tübingen, Department für Frauengesundheit
| | - SY Brucker
- Universitätsfrauenklinik Tübingen, Department für Frauengesundheit
| | - A Hartkopf
- Universitätsfrauenklinik Tübingen, Department für Frauengesundheit
| |
Collapse
|
11
|
Matovina S, Engler T, Müller H, Grischke EM, Hahn M, Brucker SY, Hartkopf AD. Vergleich von biosimilarem Trastuzumab (ABP 980, Kanjinti®) mit dem Originalantikörper (Herceptin®) anhand der pCR-Rate nach neoadjuvanter Therapie bei frühem HER2-positivem Mammakarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | - T Engler
- Universitätsfrauenklinik Tübingen
| | - H Müller
- Universitätsfrauenklinik Tübingen
| | | | - M Hahn
- Universitätsfrauenklinik Tübingen
| | | | | |
Collapse
|
12
|
Mittelstadt S, Grube M, Hartkopf A, Engler T, Walter CB, Oberlechner E, Krämer B, Grischke EM, Brucker SY, Fischer A, Staebler A, Kommoss S. Charakterisierung von Langzeitüberleberinnen nach Ovarialkarzinom im Patientenkollektiv der Universitätsfrauenklinik Tübingen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | - M Grube
- Universitätsfrauenklinik Tübingen
| | | | - T Engler
- Universitätsfrauenklinik Tübingen
| | | | | | - B Krämer
- Universitätsfrauenklinik Tübingen
| | | | | | | | | | | |
Collapse
|
13
|
Volmer L, Engler T, Staebler A, Hahn M, Kommoss S, Krämer B, Brucker S, Hartkopf A. Erstmanifestation eines Muir-Torre-Syndroms. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Volmer
- Universitätsfrauenklinik Tübingen
| | - T Engler
- Universitätsfrauenklinik Tübingen
| | | | - M Hahn
- Universitätsfrauenklinik Tübingen
| | | | - B Krämer
- Universitätsfrauenklinik Tübingen
| | | | | |
Collapse
|
14
|
Heitz F, Krämer P, Talhouk A, MA B, DS C, ES C, Scheunhage D, RF H, Senz J, Leung S, Hartkopf A, Krämer B, Brucker S, du Bois A, Harter P, FK K, Heublein S, Kommoss F, JN M, Singh N, Bosse T, Köbel M, MS A, Staebler A, Kommoss S. Anwendung der molekularen Risikostratifikation des Endometriums auf das endometrioide Ovarialkarzinom- eine retrospektive, internationale Multizenterstudie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- F Heitz
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - P Krämer
- Tuebingen University Hospital, Department of Women’s Health
- University of British Columbia, Department of Obstetrics and Gynecology
| | - A Talhouk
- University of British Columbia, Department of Obstetrics and Gynecology
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
| | - Brett MA
- McMaster University, Department of Pathology and Molecular Medicine
| | - Chiu DS
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
- BC Cancer Research Centre, Department of Molecular Oncology
| | - Cairns ES
- University of British Columbia, Department of Obstetrics and Gynecology
| | - D Scheunhage
- Leiden University Medical Centre (LUMC), Department of Pathology
| | - Hammond RF
- Barts Health National Health Service Trust, Department of Pathology
| | - J Senz
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
- University of British Columbia, Department of Pathology and Laboratory Medicine
| | - S Leung
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
- University of British Columbia, Department of Pathology and Laboratory Medicine
| | - A Hartkopf
- Tuebingen University Hospital, Department of Women’s Health
| | - B Krämer
- Tuebingen University Hospital, Department of Women’s Health
| | - S Brucker
- Tuebingen University Hospital, Department of Women’s Health
| | - A du Bois
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - P Harter
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - Kommoss FK
- Heidelberg University Hospital, Institute of Pathology
| | - S Heublein
- Heidelberg University Hospital, Heidelberg and National Center for Tumor Diseases, Department of Obstetrics and Gynecology
| | - F Kommoss
- Medizin Campus Bodensee, Institute of Pathology
| | - McAlpine JN
- University of British Columbia, Department of Obstetrics and Gynecology
- BC Cancer Research Centre, Department of Molecular Oncology
| | - N Singh
- Barts Health National Health Service Trust, Department of Pathology
| | - T Bosse
- Leiden University Medical Centre (LUMC), Department of Pathology
| | - M Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary
| | - Anglesio MS
- University of British Columbia, Department of Obstetrics and Gynecology
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
| | - A Staebler
- University Hospital Tuebingen, Institute of Pathology and Neuropathology
| | - S Kommoss
- Tuebingen University Hospital, Department of Women’s Health
| |
Collapse
|
15
|
Haßdenteufel K, Brusniak K, Feißt M, Sebesteny L, Engler T, Hartkopf AD, Graf J, Schneeweiss A, Wallwiener M, Deutsch TM. EQ-VAS zur Therapieevaluation von palliativen Chemotherapien beim metastasierten Mammakarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | - M Feißt
- Institut für Medizinische Biometrie und Informatik
| | | | - T Engler
- Universitätsfrauenklinik Tübingen
| | | | - J Graf
- Universitätsfrauenklinik Tübingen
| | - A Schneeweiss
- Nationales Centrum für Tumorerkrankungen (NCT)
- Deutsches Krebsforschungszentrum (DKFZ)
| | | | - TM Deutsch
- Universitätsfrauenklinik Heidelberg
- Nationales Centrum für Tumorerkrankungen (NCT)
| |
Collapse
|
16
|
Deutsch TM, Stefanovic S, Riethdorf S, Fischer C, Feißt M, Pantel K, Hartkopf AD, Fremd C, Schütz F, Schneeweiss A, Wallwiener M. Schwellenwert-Analyse der CTC-Veränderung unter Therapie zur Definition eines Therapieansprechens beim metastasierten Mammakarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | - S Riethdorf
- Institut für Tumorbiologie, Universitätsklinikum Hamburg-Eppendorf
| | - C Fischer
- Universitäts-Frauenklinik Heidelberg
| | - M Feißt
- Institut für Medizinische Biometrie und Informatik, Universitätsklinikum Heidelberg
| | - K Pantel
- Institut für Tumorbiologie, Universitätsklinikum Hamburg-Eppendorf
| | | | - C Fremd
- Nationales Centrum für Tumorerkrankungen (NCT)
| | - F Schütz
- Universitäts-Frauenklinik Heidelberg
| | | | | |
Collapse
|
17
|
Stefanovic S, Deutsch TM, Wirtz R, Hartkopf A, Sinn P, Riedel F, Sütterlin M, Schneeweiss A, Wallwiener M. Impact of mRNA-assessed intrinsic subtype conversion between primary and metastatic breast cancer on survival. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Stefanovic
- Universitätsfrauenklinik Mannheim, Universitätsklinikum Mannheim, Universität Heidelberg
| | - TM Deutsch
- Universitätsfrauenklinik, Universitätsklinikum Heidelberg
| | - R Wirtz
- Stratifyer Molecular Pathology GmbH
| | - A Hartkopf
- Universitätsfrauenklinik, Universitätsklinikum Tübingen
| | - P Sinn
- Institut für Pathologie, Universitätsklinikum Heidelberg
| | - F Riedel
- Universitätsfrauenklinik, Universitätsklinikum Heidelberg
| | - M Sütterlin
- Universitätsfrauenklinik Mannheim, Universitätsklinikum Mannheim, Universität Heidelberg
| | - A Schneeweiss
- Nationales Centrum für Tumorerkrankungen (NCT)
- Deutsches Krebsforschungszentrum (DKFZ)
| | - M Wallwiener
- Universitätsfrauenklinik, Universitätsklinikum Heidelberg
| |
Collapse
|
18
|
Stefanovic S, TM D, Riethdorf S, Fischer C, Hartkopf A, Sinn P, Feisst M, Pantel K, Hennigs A, Golatta M, Sütterlin M, Schneeweiss A, Wallwiener M. Receptor discordance between primary tumor and metastasis influences CTC-status. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Stefanovic
- Universitätsfrauenklinik, Universitätsklinikum Mannheim, Universität Heidelberg
| | - Deutsch TM
- Universitätsfrauenklinik, Universitätsklinikum Heidelberg
| | - S Riethdorf
- Institut für Tumorbiologie, Universitätsklinikum Hamburg-Eppendorf
| | - C Fischer
- Universitätsfrauenklinik, Universitätsklinikum Heidelberg
| | - A Hartkopf
- Universitätsfrauenklinik, Universitätsklinikum Tübingen
| | - P Sinn
- Institut für Pathologie, Universitätsklinikum Heidelberg
| | - M Feisst
- Institut für Medizinische Biometrie und Informatik, Universitätsklinikum Heidelberg
| | - K Pantel
- Institut für Tumorbiologie, Universitätsklinikum Hamburg-Eppendorf
| | - A Hennigs
- Universitätsfrauenklinik, Universitätsklinikum Heidelberg
| | - M Golatta
- Universitätsfrauenklinik, Universitätsklinikum Heidelberg
| | - M Sütterlin
- Universitätsfrauenklinik, Universitätsklinikum Mannheim, Universität Heidelberg
| | - A Schneeweiss
- Nationales Centrum für Tumorerkrankungen (NCT)
- Deutsches Krebsforschungszentrum (DKFZ)
| | - M Wallwiener
- Universitätsfrauenklinik, Universitätsklinikum Heidelberg
| |
Collapse
|
19
|
Huebner H, Kurbacher C, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, Taran FA, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Untsch M, Janni W, Fehm TN, Kohlberg HC, Wallwiener D, Brucker SY, Schneeweiss A, Ettl J, Ruebner M, PA F. Nutzung eines molekularen Registers (PRAEGNANT) zur Patienten-Selektion und Biomarker-Analyse für die SHERBOC Studie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- H Huebner
- Frauenklinik, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Europäische Metropolregion Nürnberg (CCC ER-EMN), Friedrich Alexander Universität Erlangen-Nürnberg
| | | | | | | | - MP Lux
- Klinik für Gynäkologie und Geburtshilfe Frauenklinik St. Louise
- St. Josefs-Krankenhaus
| | - J Huober
- Frauenklinik, Universitätsklinikum Ulm
| | - B Volz
- Hochschule für angewandte Wissenschaften Ansbach, Fakultät Wirtschaft
| | - FA Taran
- Frauenklinik, Universitätsklinikum Tübingen
| | | | | | - L Häberle
- Frauenklinik, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Europäische Metropolregion Nürnberg (CCC ER-EMN), Friedrich Alexander Universität Erlangen-Nürnberg
| | - D Lüftner
- Charite Berlin, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CVK)
| | - M Wallwiener
- Universitätsklinikum Heidelberg, Zentrum für gynäkologische Krebserkrankungen
| | - V Müller
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf
| | - MW Beckmann
- Frauenklinik, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Europäische Metropolregion Nürnberg (CCC ER-EMN), Friedrich Alexander Universität Erlangen-Nürnberg
| | | | - M Untsch
- Geburtshilfe und Gynäkologie, HELIOS Klinikum Berlin-Buch
| | - W Janni
- Frauenklinik, Universitätsklinikum Ulm
| | - TN Fehm
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Düsseldorf
| | | | | | - SY Brucker
- Frauenklinik, Universitätsklinikum Tübingen
| | - A Schneeweiss
- Nationales Centrum für Tumorerkrankungen, Universitätsklinikum Heidelberg
| | - J Ettl
- Frauenklinik, Klinikum rechts der Isar, Technische Universität München
| | - M Ruebner
- Frauenklinik, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Europäische Metropolregion Nürnberg (CCC ER-EMN), Friedrich Alexander Universität Erlangen-Nürnberg
| | | |
Collapse
|
20
|
El-Balat A, Marmé F, Sehouli J, Welslau M, Grabowski J, Hartkopf A, Glowik R, Hilpert F. Olaparib routine clinical practice in Germany – Quality of life interim results of the non-interventional C-PATROL study. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A El-Balat
- Universitätsklinikum Frankfurt, Klinik für Frauenheilkunde und Geburtshilfe
| | - F Marmé
- University Medical Centre Mannheim, Medical Faculty Mannheim, Department of Gynecology
| | - J Sehouli
- Department of Gynecology with Center for Oncological Surgery, Charité Medical University, Berlin, Germany
| | - M Welslau
- Medical office for hemato-oncology, Aschaffenburg
| | - J.P Grabowski
- Department of Gynecology and Center for Oncological Surgery, Charité Medical University, Berlin, Germany
| | - A Hartkopf
- University Hospital of Tuebingen, Center for Women’s Health
| | | | - F Hilpert
- Oncology Centre at Jerusalem Hospital Hamburg
| |
Collapse
|
21
|
Hack CC, Häberle L, Brucker SY, Janni W, Volz B, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kuemmel S, Martin B, Thomssen C, Graf H, Wolf C, Lux MP, Bayer CM, Rauh C, Almstedt K, Gass P, Heindl F, Brodkorb T, Willer L, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Rack B, Beckmann MW, Fehm T, Rody A, Maass N, Hein A, Fasching PA, Nabieva N. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. Breast 2020; 50:11-18. [PMID: 31958661 PMCID: PMC7377331 DOI: 10.1016/j.breast.2019.12.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Revised: 12/30/2019] [Accepted: 12/31/2019] [Indexed: 12/25/2022] Open
Abstract
Background Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment — e.g., with letrozole. Letrozole often induces myalgia/limb pain and arthralgia, with potential noncompliance and treatment termination. This analysis investigated whether CAM before aromatase inhibitor (AI) therapy is associated with pain development and the intensity of AI-induced musculoskeletal syndrome (AIMSS) during the first year of treatment. Patients and methods The multicenter phase IV PreFace study evaluated letrozole therapy in postmenopausal, hormone receptor–positive patients with early BC. Patients were asked about CAM use before, 6 months after, and 12 months after treatment started. They recorded pain every month for 1 year in a diary including questions about pain and numeric pain rating scales. Data were analyzed for patients who provided pain information for all time points. Results Of 1396 patients included, 901 (64.5%) had used CAM before AI treatment. Throughout the observation period, patients with CAM before AI treatment had higher pain values, for both myalgia/limb pain and arthralgia, than non-users. Pain increased significantly in both groups over time, with the largest increase during the first 6 months. No significant difference of pain increase was noted regarding CAM use. Conclusions CAM use does not prevent or improve the development of AIMSS. Pain intensity was generally greater in the CAM group. Therefore, because of the risk of non-compliance and treatment discontinuation due to the development of higher pain levels, special attention must be paid to patient education and aftercare in these patients. Pain levels of myalgia/limb pain and arthralgia increase under letrozole intake. Within one year pain levels increase in both, CAM users as well as non-CAM users. In CAM users pain levels were higher at all time points than in non-CAM users. The greatest increase of pain levels was noted in the first six treatment months. CAM does not prevent or improve the development of myalgia/limb pain and arthralgia.
Collapse
Affiliation(s)
- C C Hack
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - L Häberle
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Biostatistics Unit, Department of Gynecology, Erlangen University Hospital, Erlangen, Germany
| | - S Y Brucker
- Department of Gynecology, University of Tübingen, Tübingen, Germany
| | - W Janni
- Department of Gynecology, Ulm University Hospital, Ulm, Germany
| | - B Volz
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - C R Loehberg
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; St. Theresien Hospital, Nuremberg, Germany
| | - A D Hartkopf
- Department of Gynecology, University of Tübingen, Tübingen, Germany
| | - C-B Walter
- Department of Gynecology, University of Tübingen, Tübingen, Germany
| | - G Baake
- Oncological Medical Practice Pinneberg, Pinneberg, Germany
| | - A Fridman
- Breast Center, Department of Obstetrics and Gynecology, University of Cologne Hospital, Cologne, Germany; Evangelisches Krankenhaus Kalk, Cologne, Germany
| | - W Malter
- Breast Center, Department of Obstetrics and Gynecology, University of Cologne Hospital, Cologne, Germany
| | - R Wuerstlein
- Breast Center, Department of Obstetrics and Gynecology, University of Cologne Hospital, Cologne, Germany; Breast Center, Department of Gynecology and Obstetrics and CCC Munich, University of Munich (LMU), Munich, Germany
| | - N Harbeck
- Breast Center, Department of Obstetrics and Gynecology, University of Cologne Hospital, Cologne, Germany; Breast Center, Department of Gynecology and Obstetrics and CCC Munich, University of Munich (LMU), Munich, Germany
| | - O Hoffmann
- Department of Gynecology, Essen University Hospital, Essen, Germany
| | - S Kuemmel
- Breast Unit, Essen Mitte Clinics, Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany
| | - B Martin
- Tuttlingen Clinic, Tuttlingen, Germany
| | - C Thomssen
- Department of Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany
| | - H Graf
- Helios Clinics Meiningen, Meiningen, Germany
| | - C Wolf
- Ulm Medical Center, Ulm, Germany
| | - M P Lux
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - C M Bayer
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - C Rauh
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - K Almstedt
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Department of Gynecology, Mainz University Hospital, Mainz, Germany
| | - P Gass
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - F Heindl
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - T Brodkorb
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - L Willer
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - C Lindner
- Agaplesion Diakonie Clinic Hamburg, Hamburg, Germany
| | - H-C Kolberg
- Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
| | - P Krabisch
- Department of Gynecology, Klinikum Chemnitz gGmbH, Chemnitz, Germany
| | - M Weigel
- Department of Gynecology, Leopoldina Hospital Schweinfurt, Schweinfurt, Germany
| | - D Steinfeld-Birg
- Gynecologic Onocologic Practice Steinfeld-Birg, Augsburg, Germany
| | - A Kohls
- Protestant County Hospital of Ludwigsfelde-Teltow, Ludwigsfelde-Teltow, Germany
| | - C Brucker
- Department of Gynecology and Obstetrics, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany
| | - V Schulz
- Gynecologic Practice Abts+partner, Kiel, Germany
| | - G Fischer
- Mittweida Hospital gGmbH, Mittweida, Germany
| | - V Pelzer
- Department of Gynecology, GFO Clinics Bonn, Bonn, Germany
| | - B Rack
- Department of Gynecology, Ulm University Hospital, Ulm, Germany
| | - M W Beckmann
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - T Fehm
- Department of Gynecology, University of Tübingen, Tübingen, Germany; Department of Gynecology, Heinrich Heine University of Dusseldorf, Dusseldorf, Germany
| | - A Rody
- Department of Gynecology, Campus Lübeck, Schleswig-Holstein University Hospital, Schleswig-Holstein, Germany
| | - N Maass
- Department of Gynecology, Campus Kiel, Schleswig-Holstein University Hospital, Schleswig-Holstein, Germany
| | - A Hein
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - P A Fasching
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
| | - N Nabieva
- Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| |
Collapse
|
22
|
Sehouli J, Hilpert F, Welslau M, Grabowski J, Seitz J, El-Balat A, Hartkopf A, Glowik R, Marmé F. Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Müller V, Huober J, Volz B, Overkamp F, Kolberg HC, Hadji P, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lüftner DI, Wallwiener M, Taran FA, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt A, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Fehm TN, Brucker SY, Wallwiener D, Schneeweiss A, Fasching PA, Tesch H. Abstract OT1-11-02: PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/ metastatic setting (NCT02338167). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
During the last decades the treatment of advanced breast cancer (ABC) patients has improved due to a variety of new treatment strategies. Nevertheless, many ABC patients are faced with limited prognosis, and their treatment remains a challenge. New targeted therapies complement the well-established treatment options for ABC (CDK4/6 inhibition, anti-endocrine, chemotherapy, antibody based and bone related therapies), leading to improved treatment regimens tailored to the needs of special patient sub-populations.
SPECIFIC AIMS/TRIAL DESIGN
The PRAEGNANT network study is conducted as an academic, prospective registry and diagnostic translational study, accompanied by biomaterial collection. The pilot phase in more than 60 centers aims at including 3500 ABC patients. The primary objective is to discover biomarkers, which predict progression free survival (PFS). Secondary objectives include overall survival (OS), breast cancer specific survival, objective response rate, patient reported outcomes (PRO), description of therapies used in the metastatic setting, therapy adherence, health economics for patients with ABC, incidence of (serious) adverse events and big data/ machine learning algorithms. The exploratory objectives comprise correlations of gene alterations and their influence on OS, PFS, side effects and PRO. Exploratory biomarkers are assessed at baseline and at every change of therapy. These biomarkers include gene expression profiling of the primary tumor and corresponding metastasis, somatic mutations (measured in the tumor and in circulating tumor DNA), germline genetic variations, epigenetic changes and miRNA variations. Furthermore, plasma and serum markers are assessed. If actionable molecular alterations are detected patients are informed and recruited into suitable studies if available.
ELIGIBILITY CRITERIA:
Any adult patient (>18 years) with the diagnosis of ABC and who is willing and able to sign the informed consent can be enrolled.
STATISTICAL METHODS/TARGET ACCRUAL:
The PRAEGNANT study as a prospective real world registry and diagnostic translational study aims to identify biomarkers in ABC patients, which may predict PFS. Target accrual for the pilot phase is 3500 patients. Each patient will be documented for up to 36 months with an estimated median PFS for all patients of 11 months across all treatment lines.
Citation Format: Müller V, Huober J, Volz B, Overkamp F, Kolberg H-C, Hadji P, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lüftner DI, Wallwiener M, Taran F-A, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt A, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Fehm TN, Brucker SY, Wallwiener D, Schneeweiss A, Fasching PA, Tesch H. PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/ metastatic setting (NCT02338167) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-11-02.
Collapse
Affiliation(s)
- V Müller
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Huober
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - B Volz
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - F Overkamp
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - H-C Kolberg
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - P Hadji
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - L Haeberle
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Ettl
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - AD Hartkopf
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - MP Lux
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - DI Lüftner
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - F-A Taran
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - MW Beckmann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - E Belleville
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - P Wimberger
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Hielscher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Geberth
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Lermann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - A Abenhardt
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Kurbacher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - R Wuerstlein
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Thomssen
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Untch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - W Janni
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - TN Fehm
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - SY Brucker
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - D Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - A Schneeweiss
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - PA Fasching
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - H Tesch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| |
Collapse
|
24
|
Lux MP, Hartkopf AD, Huober J, Volz B, Taran FA, Overkamp F, Hadji P, Tesch H, Haeberle L, Ettl J, Lueftner DI, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg HC. Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose:
This analysis describes comprehensive real-world data concerning the use of anti-HER2 therapies in HER2 positive metastatic breast cancer (MBC). Specifically, it describes the therapy patterns of treatments with trastuzumab (TZM), pertuzumab+trastuzumab (PTZ/TZM), lapatinib (LAP) and trastuzumab emtansine (T-DM1).
Methods:
The PRAEGNANT study is a real-time, real-world registry for patients with MBC. Patients can be registered for PRAEGNANT at any time during the course of their metastatic disease and are followed up until death. All therapy lines are documented. This analysis presents the utilization of anti-HER2 therapies as well as therapy sequences.
Results:
Of 1936 patients within PRAEGNANT at the time of database closure 451 were HER2 positive (23.3%). Within the analysis set (417 patients after an unilateral breast cancer diagnosis), of which 53% were included in PRAEGNANT in the 1stline setting, 241 were treated with TZM (58%), 237 with PTZ (57%), 85 with LAP (20%) and 125 with T-DM1 (30%) during the course of their therapies. The sequence PTZ/TZMàT-DM1 was given to 51 patients (12%). Worse ECOG, negative hormone receptor status, and visceral or brain metastases were associated with a more frequent use of this therapy sequence. Most patients received T-DM1 after a therapy with pertuzumab.
Conclusions:
Both novel therapies (PTZ/TZM and T-DM1) are utilized in a high proportion of HER2 positive breast cancer patients. As most patients receive T-DM1 after pertuzumab real world data might help to understand whether this sequence has similar efficacy like in the approval study.
Citation Format: Lux MP, Hartkopf AD, Huober J, Volz B, Taran F-A, Overkamp F, Hadji P, Tesch H, Haeberle L, Ettl J, Lueftner DI, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg H-C. Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-37.
Collapse
Affiliation(s)
- MP Lux
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - AD Hartkopf
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Huober
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - B Volz
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - F-A Taran
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - F Overkamp
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - P Hadji
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - H Tesch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - L Haeberle
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Ettl
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - DI Lueftner
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - V Müller
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - MW Beckmann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - E Belleville
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - P Wimberger
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Hielscher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Geberth
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - J Lermann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - W Abenhardt
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Kurbacher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - R Wuerstlein
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - C Thomssen
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - M Untch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - PA Fasching
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - W Janni
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - TN Fehm
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - D Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - SY Brucker
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - A Schneeweiss
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| | - H-C Kolberg
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Erlangen University Hospital Comprehensive Cancer Center Erlangen-EMN Friedrich-Alexander University, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Kli
| |
Collapse
|
25
|
Schneeweiss A, Lux MP, Hartkopf AD, Volz B, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Lüftner DI, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Overkamp F, Huober J, Taran FA, Janni W, Wallwiener D, Brucker SY, Fasching PA, Fehm TN. Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Studies leading to the approval of trastuzumab emtansine (T-DM1) have been conducted without pertuzumab as previous therapy. Therefore data about patient characteristics and the efficacy of T-DM1 after a treatment with pertuzumab is scarce. Aim of this study was to analyze a real world patient cohort of advanced breast cancer (aBC) patients, who were treated with T-DM1 after a treatment containing pertuzumab in the metastatic setting with regard to patient characteristics and progression free survival (PFS).
Methods
The PRAEGNANT metastatic breast cancer registry (NCT02338167) is a prospective registry for metastatic breast cancer patients with focus on molecular biomarkers. Patients of all therapy lines with any kind of treatment are eligible for this registry. Collected data comprises all relevant patient and tumor characteristics, therapies, adverse events, quality of life, patient reported outcomes, response and survival (PFS/OS). Here we report on the patient characteristics and PFS data for HER2 positive patients treated with T-DM1 after a treatment with pertuzumab. Patients had to be included before or at the beginning of the T-DM1 therapy.
Results
A total of 58 patients could be identified, who were suitable for the analysis. Of those 34 were treated in the second line, 14 in the third line and 10 in the fourth line or higher. Most of the pertuzumab therapies before T-DM1 were conducted in first line (n=46; 79.3%). Median PFS for all patients was 4.8 months (95% CI: 3.0-7.8 months). Median PFS for patients treated in the 3rdline and 4thline or higher was 4.2 months(95%CI: 2.3 - NA) and 4.0 months (95%CI: 1.8-N.A.), respectively. In patients treated 2ndline with T-DM1 PFS was 7.7 months (95%CI: 2.8 – 12.2).
Conclusion
T-DM1 is effective as 2ndand further line therapy following pretreatment with pertuzumab. Overall PFS was about 5 months with 7.7 months as 2nd-line therapy. The PFS in higher therapy lines might be shorter. As the sample size of this real world cohort was rather low and analyses have to be considered exploratory, this data need to be confirmed in studies with a larger sample size.
Citation Format: Schneeweiss A, Lux MP, Hartkopf AD, Volz B, Kolberg H-C, Hadji P, Tesch H, Haeberle L, Ettl J, Lüftner DI, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Lermann J, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Overkamp F, Huober J, Taran F-A, Janni W, Wallwiener D, Brucker SY, Fasching PA, Fehm TN. Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-22.
Collapse
Affiliation(s)
- A Schneeweiss
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - MP Lux
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - AD Hartkopf
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - B Volz
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - H-C Kolberg
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - P Hadji
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - H Tesch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - L Haeberle
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - J Ettl
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - DI Lüftner
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - M Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - V Müller
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - MW Beckmann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - E Belleville
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - P Wimberger
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - C Hielscher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - M Geberth
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - J Lermann
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - W Abenhardt
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - C Kurbacher
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - R Wuerstlein
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - C Thomssen
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - M Untch
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - F Overkamp
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - J Huober
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - F-A Taran
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - W Janni
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - D Wallwiener
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - SY Brucker
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - PA Fasching
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| | - TN Fehm
- Hamburg-Eppendorf University Medical Center, Hamburg, Germany; Ulm University Hospital, Ulm, Germany; Ulm University Hospital, Erlangen-Nuremberg, Germany; OncoConsult Hamburg GmbH, Hamburg, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; University Hospital Erlangen, Erlangen-Nuremberg, Germany; Klinikum rechts der Isar Technical University of Munich, Munich, Germany; University of Tuebingen, Tuebingen, Germany; Charité University Hospital Berlin Campus Benjamin Franklin Department of Hematology Oncology and Tumour Immunology, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; Carl Gustav Carus University, TU Dresden, Dresden, Germany and National Center for Tumor Diseases and TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Manneim, Germany; Klinikum Bayreut, Bayreuth, Germany; MVZ Onkologie Onkologie im Elisenhof, Munich
| |
Collapse
|
26
|
Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, Pierga JY, Hoffmann O, Beckmann MW, Rydén L, Fehm T, Aft R, Montserrat S, Walter V, Rack B, Schuetz F, Borgen E, Ta MH, Bittner AK, Fasching P, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M, Jueckstock J, Domschke C, Bidard FC, Kasimir-Bauer S, Schoenfisch B, Kurt AG, Wallwiener M, Gebauer G, Wallwiener D, Janni W, Pantel K. Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs5-07] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
As early breast cancer might relapse even after complete removal of breast and lymphnodes, the disease must persist in secondary sites. The detection of disseminated tumor cells (DTC) in the bone marrow (BM) has been described as a surrogate of residual disease. Various trials showed an impaired prognosis of DTC positive early breast cancer (EBC) patients. The PADDY (Pooled Analysis of DTC Detection in Early Breast Cancer) study is a large international pooled analysis that aimed to assess the prognostic impact of DTC detection in patients with EBC.
Methods
A pre-specified protocol was followed, and centers known to practice BM sampling for DTC detection were contacted for individual patient data. Patients with EBC, with available follow-up data and BM sampling before any anti-cancer treatment were eligible. BM aspirates were collected at the time of primary surgery. DTC were identified by antibody (A45-B/B3, AE1/AE3, 2E11 and E29) staining against cytokeratin. The DTC status was compared to other prognostic factors using the chi-squared test. Univariate log-rank test and multivariate cox regression were used to compare survival of DTC positive versus DTC negative patients.
Results
Individual data from 10,320 patients (11 centers from Europe and USA) were included with a median follow-up of 91 months. Of all patients, 2,823 (27.4 %) were DTC positive. DTC detection was associated with higher tumor grade, higher T stage, nodal positivity, ER and PR negativity, and HER2 positivity (all p<0.001). In univariate analyses, overall, breast cancer specific, disease-free and distant disease-free survival (OS, BCSS, DFS, DDFS) were significantly shorter in DTC positive patients with p-values of <0.001. Multivariate analyses showed the DTC status to be an independent prognostic marker for OS, BCSS, DFS and DDFS with hazard ratios (HR) and 95%-confidence intervals (CI) of 1.23 (95%-CI: 1.06-1.42, p=0.007), 1.38 (95%-CI: 1.11-1.72, p=0.004), 1.29 (95%-CI: 1.10-1.50, p=0.001) and 1.32 (95%-CI: 1.10-1.58, p=0.003), respectively.
Conclusions
Detection of DTC in the bone marrow is an independent prognostic marker in patients with non-metastatic breast cancer. Further studies should investigate the impact of DTC on metastatic cancer progression and their role for clinical decision making.
Citation Format: Hartkopf AD, Brucker SY, Taran F-A, Harbeck N, von Au A, Naume B, Pierga J-Y, Hoffmann O, Beckmann MW, Rydén L, Fehm T, Aft R, Montserrat S, Walter V, Rack B, Schuetz F, Borgen E, Ta M-H, Bittner A-K, Fasching P, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M, Jueckstock J, Domschke C, Bidard F-C, Kasimir-Bauer S, Schoenfisch B, Kurt AG, Wallwiener M, Gebauer G, Wallwiener D, Janni W, Pantel K. International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS5-07.
Collapse
Affiliation(s)
- AD Hartkopf
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - SY Brucker
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F-A Taran
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - N Harbeck
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A von Au
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - B Naume
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J-Y Pierga
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - O Hoffmann
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - MW Beckmann
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - L Rydén
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Fehm
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - R Aft
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Montserrat
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - V Walter
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - B Rack
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F Schuetz
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - E Borgen
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M-H Ta
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A-K Bittner
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Fasching
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Fernö
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - N Krawczyk
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Weilbaecher
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Margelí
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Hahn
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Jueckstock
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - C Domschke
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F-C Bidard
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Kasimir-Bauer
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - B Schoenfisch
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - AG Kurt
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Wallwiener
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - G Gebauer
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Wallwiener
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - W Janni
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Pantel
- University of Tuebingen, Tuebingen, Germany; Breast Center, University of Munich (LMU), Munic, Germany; Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany; Oslo University Hospital - and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Institut Curie, Paris and Saint Cloud, Paris, France; University Hospital of Essen, Essen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; Lund University, Lund, Sweden; Duesseldorf University Hospital, Duesseldorf, Germany; Washington University, St. Louis, MO; Hospital Germans Trias I Pujol, Badalona, Spain; Ulm University Hospital, Ulm, Germany; Oslo University Hospital, Oslo, Norway; ICO-Badalona, Medical Oncology Service. B-ARGO, Badalona, Germany; Asklepios Klinik Barmbek and Nord-Heidberg, Hamburg, Spain; Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
27
|
Banys-Paluchowski M, Fehm T, Witzel I, Aktas B, Fasching PA, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer EF, Müller V. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1675453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- M Banys-Paluchowski
- Department of Gynecology and Obstetrics, Marienkrankenhaus Hamburg, Hamburg, Germany
| | - T Fehm
- Department of Obstetrics and Gynecology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - I Witzel
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - B Aktas
- Department of Obstetrics and Gynecology, University Hospital Leipzig, Leipzig, Germany
| | - PA Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - A Hartkopf
- Department of Obstetrics and Gynecology, University Hospital Tübingen, University of Tübingen, Tübingen, Germany
| | - W Janni
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - S Kasimir-Bauer
- Department of Obstetrics and Gynecology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - K Pantel
- Department of Tumour Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - G Schön
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany
| | - B Rack
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - S Riethdorf
- Department of Tumour Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - EF Solomayer
- Department of Gynecology and Obstetrics, Saarland University Hospital, Homburg/Saar, Germany
| | - V Müller
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
28
|
Bosse K, Oberlechner E, Hoffmann A, Fugunt R, Böer B, Gruber I, Helms G, Hoopmann U, Röhm C, Hartkopf A, Komoss S, Faust U, Pohle A, Dufke A, Nguyen H, Kehrer M, Schroeder C, Heinrich T, Rieß O, Staebler A, Vogel U, Taran FA, Brucker SY, Marx M, Wallwiener D, Hahn M. Prädiktive Testung bei Familienangehörigen von BRCA1, BRCA2 und CHEK2 Mutationsträgerinnen am Universitätsbrustzentrum Tübingen – eine klinische retrospektive unizentrische Kohortenstudie. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- K Bosse
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
- Institut für Medizinische Genetik und angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - E Oberlechner
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - A Hoffmann
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - R Fugunt
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - B Böer
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - I Gruber
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - G Helms
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - U Hoopmann
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - C Röhm
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - A Hartkopf
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - S Komoss
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - U Faust
- Institut für Medizinische Genetik und angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - A Pohle
- Institut für Medizinische Genetik und angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - A Dufke
- Institut für Medizinische Genetik und angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - H Nguyen
- Institut für Medizinische Genetik und angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - M Kehrer
- Institut für Medizinische Genetik und angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - C Schroeder
- Institut für Medizinische Genetik und angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - T Heinrich
- Institut für Medizinische Genetik und angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - O Rieß
- Institut für Medizinische Genetik und angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - A Staebler
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - U Vogel
- Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - FA Taran
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - SY Brucker
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - M Marx
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - D Wallwiener
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| | - M Hahn
- Department für Frauengesundheit, Universitätsfauenklinik Tübingen, Tübingen, Deutschland
| |
Collapse
|
29
|
Fischer CL, Deutsch TM, Riethdorf S, Nees J, Hartkopf AD, Schönfisch B, Domschke C, Sprick MR, Schütz F, Brucker SY, Stefanovic S, Sohn C, Pantel K, Trumpp A, Schneeweiss A, Wallwiener M. Vergleich der Anzahl zirkulierender Tumorzellen mit dem Proliferationsmarker Ki-67 beim metastasierten Mammakarzinom. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- CL Fischer
- Universitäts-Frauenklinik Heidelberg, Heidelberg, Deutschland
| | - TM Deutsch
- Universitäts-Frauenklinik Heidelberg, Heidelberg, Deutschland
| | - S Riethdorf
- Institut für Tumorbiologie, Universitäts-Klinikum Hamburg-Eppendorf, Hamburg, Deutschland
| | - J Nees
- Universitäts-Frauenklinik Heidelberg, Heidelberg, Deutschland
| | - AD Hartkopf
- Universitäts-Frauenklinik Tübingen, Tübingen, Deutschland
| | - B Schönfisch
- Universitäts-Frauenklinik Tübingen, Tübingen, Deutschland
| | - C Domschke
- Nationales Centrum für Tumorerkrankungen, Heidelberg, Deutschland
| | - MR Sprick
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmBH), Heidelberg, Deutschland
| | - F Schütz
- Nationales Centrum für Tumorerkrankungen, Heidelberg, Deutschland
| | - SY Brucker
- Universitäts-Frauenklinik Tübingen, Tübingen, Deutschland
| | - S Stefanovic
- Nationales Centrum für Tumorerkrankungen, Heidelberg, Deutschland
| | - C Sohn
- Nationales Centrum für Tumorerkrankungen, Heidelberg, Deutschland
| | - K Pantel
- Institut für Tumorbiologie, Universitäts-Klinikum Hamburg-Eppendorf, Hamburg, Deutschland
| | - A Trumpp
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmBH), Heidelberg, Deutschland
- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Deutschland
| | - A Schneeweiss
- Universitäts-Frauenklinik Heidelberg, Heidelberg, Deutschland
- Nationales Centrum für Tumorerkrankungen, Heidelberg, Deutschland
| | - M Wallwiener
- Nationales Centrum für Tumorerkrankungen, Heidelberg, Deutschland
| |
Collapse
|
30
|
Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching PA, Aktas B, Kasimir-Bauer S, Hartkopf A, Solomayer EF, Fehm T, Müller V. The clinical relevance of circulating tumor cells in correlation to other serum biomarkers (VEGF, HER2, EGFR, TIMP1, CAIX, RASp21) in patients with metastatic breast cancer. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
| | - I Witzel
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| | - S Riethdorf
- Department of Tumour Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| | - K Pantel
- Department of Tumour Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| | - B Rack
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Deutschland
| | - W Janni
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Deutschland
| | - PA Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Deutschland
| | - B Aktas
- Department of Obstetrics and Gynecology, University Hospital Leipzig, Leipzig, Deutschland
| | - S Kasimir-Bauer
- Department of Obstetrics and Gynecology, University Hospital Essen, University of Duisburg-Essen, Essen, Deutschland
| | - A Hartkopf
- Department of Gynecology and Obstetrics, University Hospital Tuebingen, University of Tuebingen, Tuebingen, Deutschland
| | - EF Solomayer
- Department of Gynecology and Obstetrics, Saarland University Hospital, Homburg/Saar, Deutschland
| | - T Fehm
- Department of Obstetrics and Gynecology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Deutschland
| | - V Müller
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland
| |
Collapse
|
31
|
Pasternak J, Kommoss S, Burkhardt F, Staebler A, Fend F, Schoenfisch B, Krämer B, Hartkopf AD, Wallwiener D, Brucker SY, Taran FA. Prognostic impact of pathological resection margin distance in primary squamous cell carcinoma of the vulva. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Pasternak
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - S Kommoss
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - F Burkhardt
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - A Staebler
- Institut für Pathologie und Neuropathologie, Tübingen, Deutschland
| | - F Fend
- Institut für Pathologie und Neuropathologie, Tübingen, Deutschland
| | - B Schoenfisch
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - B Krämer
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - AD Hartkopf
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - D Wallwiener
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - SY Brucker
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - FA Taran
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| |
Collapse
|
32
|
Simoes E, Graf J, Sokolov AN, Grischke EM, Hartkopf AD, Hahn M, Weiss M, Abele H, Seeger H, Brucker SY. 10-Jahres-Überlebensrate und Geburtsoutcomes bei Schwangerschafts-assoziiertem Brustkrebs. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- E Simoes
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Forschungsinstitut für Frauengesundheit, Tübingen, Deutschland
- Stabstelle Sozialmedizin, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - J Graf
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Forschungsinstitut für Frauengesundheit, Tübingen, Deutschland
- Universität Tübingen, Medizinische Fakultät, Bereich Studium und Lehre, Tübingen, Deutschland
| | - AN Sokolov
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Forschungsinstitut für Frauengesundheit, Tübingen, Deutschland
| | - EM Grischke
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - AD Hartkopf
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - M Hahn
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - M Weiss
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - H Abele
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - H Seeger
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - SY Brucker
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Forschungsinstitut für Frauengesundheit, Tübingen, Deutschland
| |
Collapse
|
33
|
Krainau N, Ehret F, Märklin J, Stauss E, Kasperkowiak A, Engler T, Schönfisch B, Heilmann W, Oberlechner E, Krämer B, Taran FA, Brucker SY, Grischke EM, Kommoss S, Hartkopf A. Chemotherapie des rezidivierten Ovarialkarzinoms: Eine retrospektive Analyse im Patientenkollektiv der Universitätsfrauenklinik Tübingen als Basis für das individuelle Patientengespräch. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- N Krainau
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - F Ehret
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - J Märklin
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - E Stauss
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - A Kasperkowiak
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - T Engler
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - B Schönfisch
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - W Heilmann
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - E Oberlechner
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - B Krämer
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - FA Taran
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - SY Brucker
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - EM Grischke
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - S Kommoss
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - A Hartkopf
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| |
Collapse
|
34
|
Stefanovic S, Wirtz R, Deutsch T, Sinn P, Hartkopf A, Schütz F, Bohlmann M, Sütterlin M, Schneeweiß A, Wallwiener M. Korrelation der CTC-Dynamik und der mRNA-quantifizierten Biomarkerkonvertierung zwischen primärem und metastasiertem Mammakarzinom. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Stefanovic
- Universitätsklinikum Mannheim, Universität Heidelberg, Mannheim, Deutschland
| | - R Wirtz
- Stratifyer Molecular Pathology GmbH, Köln, Deutschland
| | - T Deutsch
- Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - P Sinn
- Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - A Hartkopf
- Unifrauenklinik Tübingen, Tübingen, Deutschland
| | - F Schütz
- Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - M Bohlmann
- Universitätsklinikum Mannheim, Universität Heidelberg, Mannheim, Deutschland
| | - M Sütterlin
- Universitätsklinikum Mannheim, Universität Heidelberg, Mannheim, Deutschland
| | - A Schneeweiß
- Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - M Wallwiener
- Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| |
Collapse
|
35
|
Braun S, Marcu A, Billich T, Engler T, Schuster H, Taran FA, Hartkopf AD, Wallwiener D, Brucker SY, Rammensee HG, Stevanovic S, Wagner P. Entwicklung einer Multipeptidvakzine zur Therapie des Ovarialkarzinoms. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Braun
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - A Marcu
- Interfakultäres Institut für Zellbiologie, Universität Tübingen, Abteilung für Immunologie, Tübingen, Deutschland
| | - T Billich
- Interfakultäres Institut für Zellbiologie, Universität Tübingen, Abteilung für Immunologie, Tübingen, Deutschland
| | - T Engler
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - H Schuster
- Interfakultäres Institut für Zellbiologie, Universität Tübingen, Abteilung für Immunologie, Tübingen, Deutschland
| | - FA Taran
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - AD Hartkopf
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - D Wallwiener
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - SY Brucker
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - HG Rammensee
- Interfakultäres Institut für Zellbiologie, Universität Tübingen, Abteilung für Immunologie, Tübingen, Deutschland
| | - S Stevanovic
- Interfakultäres Institut für Zellbiologie, Universität Tübingen, Abteilung für Immunologie, Tübingen, Deutschland
| | - P Wagner
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| |
Collapse
|
36
|
Wagner P, Kommoss F, Kommoss S, Hartkopf AD, Pasternak I, Oberlechner E, Wallwiener M, Neis F, Abele H, Krämer B, Reisenauer C, Staebler A, Wallwiener D, Brucker SY, Taran FA. Unexpected malignant uterine pathology: incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- P Wagner
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - F Kommoss
- University of Heidelberg, Institute of Pathology, Heidelberg, Deutschland
| | - S Kommoss
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - AD Hartkopf
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - I Pasternak
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - E Oberlechner
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - M Wallwiener
- University of Heidelberg, Department of Obstetrics and Gynecology, Heidelberg, Deutschland
| | - F Neis
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - H Abele
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - B Krämer
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - C Reisenauer
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - A Staebler
- University of Tübingen, Institute of Pathology, Tübingen, Deutschland
| | - D Wallwiener
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - SY Brucker
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| | - FA Taran
- University of Tübingen, Department of Obstetrics and Gynecology, Tübingen, Deutschland
| |
Collapse
|
37
|
Keul J, Kommoss F, Karnezis AN, Wang Y, Pasternak J, Hartkopf A, Oberlechner E, Taran A, Staebler A, Schmidt D, Gilks CB, Huntsman DG, Brucker SY, Kommoss S. Sertoli-Leydigzelltumoren (SLCT) des Ovars: Dicer1- und Foxl2-Mutationsstatus als Beitrag zur Etablierung einer neuartigen, klinisch und histopathologisch relevanten Klassifikation. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Keul
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - F Kommoss
- Institut für Pathologie, Friedrichshafen, Deutschland
| | - AN Karnezis
- BC Cancer Research Centre, Vancouver, Kanada
| | - Y Wang
- BC Cancer Research Centre, Vancouver, Kanada
| | - J Pasternak
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - A Hartkopf
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - E Oberlechner
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - A Taran
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - A Staebler
- Institut für Pathologie, Tübingen, Deutschland
| | - D Schmidt
- Institut für Pathologie, Viersen, Deutschland
| | - CB Gilks
- BC Cancer Research Centre, Vancouver, Kanada
| | - DG Huntsman
- BC Cancer Research Centre, Vancouver, Kanada
| | - SY Brucker
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - S Kommoss
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| |
Collapse
|
38
|
Heilmann W, Vogel RI, Pulver T, Zhao X, Shahi M, Richter J, Klein M, Chen L, Ding R, Konecny G, Winterhoff B, Ghebre R, Taran FA, Hartkopf A, Grischke EM, Walter CB, Brucker SY, Bazzaro M, Kommoss S. USP14 als potentielle Zielstruktur neuer Therapiestrategien in der Behandlung des Endometriumkarzinoms. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- W Heilmann
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - RI Vogel
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
- Masonic Cancer Center, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - T Pulver
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - X Zhao
- Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - M Shahi
- Department of Pathology and Laboratory Medicine, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - J Richter
- Department of Pathology and Laboratory Medicine, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - M Klein
- Department of Pathology and Laboratory Medicine, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - L Chen
- Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - R Ding
- Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - G Konecny
- Gynecologic Oncology, Hematology & Oncology Department, UCLA Medical Center, Santa Monica, Vereinigte Staaten von Amerika
| | - B Winterhoff
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - R Ghebre
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - FA Taran
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - A Hartkopf
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - EM Grischke
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - CB Walter
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - SY Brucker
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| | - M Bazzaro
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
- Masonic Cancer Center, University of Minnesota, Minneapolis, Vereinigte Staaten von Amerika
| | - S Kommoss
- Universitätsfrauenklinik Tübingen, Tübingen, Deutschland
| |
Collapse
|
39
|
Graf J, Matthies L, Simoes E, Sokolov AN, Keilmann L, Sickenberger N, Wallwiener D, Taran FA, Hartkopf AD, Schneeweiss A, Wallwiener M, Brucker SY. Tablet-basierte Erhebung der gesundheitsbezogenen Lebensqualität bei adjuvantem und metastasiertem Brustkrebs: Akzeptanz und Reliabilität. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Graf
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Forschungsinstitut für Frauengesundheit, Tübingen, Deutschland
- Medizinische Fakultät, Bereich Studium und Lehre, Universität Tübingen, Tübingen, Tübingen, Deutschland
| | - L Matthies
- Universitätsklinikum Heidelberg, Abteilung für Allgemeine Frauenheilkunde und Geburtshilfe, Heidelberg, Deutschland
| | - E Simoes
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Forschungsinstitut für Frauengesundheit, Tübingen, Deutschland
- Stabstelle Sozialmedizin, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - AN Sokolov
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Forschungsinstitut für Frauengesundheit, Tübingen, Deutschland
| | - L Keilmann
- Universitätsklinikum Heidelberg, Abteilung für Allgemeine Frauenheilkunde und Geburtshilfe, Heidelberg, Deutschland
| | - N Sickenberger
- Universitätsklinikum Heidelberg, Abteilung für Allgemeine Frauenheilkunde und Geburtshilfe, Heidelberg, Deutschland
| | - D Wallwiener
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - FA Taran
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - AD Hartkopf
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - A Schneeweiss
- Universitätsklinikum Heidelberg, Abteilung für Allgemeine Frauenheilkunde und Geburtshilfe, Heidelberg, Deutschland
| | - M Wallwiener
- Universitätsklinikum Heidelberg, Abteilung für Allgemeine Frauenheilkunde und Geburtshilfe, Heidelberg, Deutschland
| | - SY Brucker
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
- Universitätsklinikum Tübingen, Department für Frauengesundheit, Forschungsinstitut für Frauengesundheit, Tübingen, Deutschland
| |
Collapse
|
40
|
Huober J, Fasching PA, Taran FA, Volz B, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lueftner D, Wallwiener M, Mueller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
For breast cancer patients with metastases which are not life threatening national and international guidelines recommend the exhaustion of all antihormonal therapeutic options before recommending chemotherapy. In Germany up to now only everolimus was an additional option to overcome endocrine resistance. CDK4/6 inhibitors recently became available in Germany (Nov 2011). Aim of this analysis was the identification of predictors for a decision against an antihormonal treatment.
Methods
The PRAEGNANT metastatic breast cancer registry (NCT02338167) is a prospective registry for metastatic breast cancer patients. Besides biomarker research the description of real-world treatment data was one of the main study aims. This analysis was restricted to first line metastatic patients who were hormone receptor (HR) positive and HER2 negative. First, predictors were identified with a multiple logistic regression model. Then patients, who received chemo or not ,were compared with regard to overall survival using Cox regression analysis with the predictors for chemotherapy from above and additionally chemo status (yes/no)
Results
A total of 389 HR-positive and HER2-negative patients with detailed treatment information were included during the 1st line therapy into PRAEGNANT. Of those 173 (44.5%) received a chemotherapy, 190 an antihormone therapy (AHT) (48.8%), and 26 (6.7%) everolimus+AHT. In the multiple logistic regression model, older patients, lower graded tumors, bone only disease and previous adjuvant chemotherapy were associated with a lower rate of first line chemotherapies. BMI and number of concomitant diseases had no influence on the choice of first line metastatic therapy. In patients with visceral metastases 58.1% were treated with a 1st line chemo, while in patients with brain metastases or bone only metastases these numbers were 55.6% and 26.9%. Grading had an influence with patients having a G1, G2 and G3 tumor receiving 1st line chemo in 28.0%, 38.4% and 63.2% of the cases respectively. Patients who received chemo seemed to have a worse overall survival than patients who did not receive chemo (adjusted HR 1.58; 95% CI, 0.89 to 2.18). However, this result was not signifcant (p = 0.12). Overall survival was primarily influenced by ECOG and location of metastasis
Conclusion
The usage of chemotherapy can be predicted with age, metastasis pattern, grading and previous use of chemotherapy. However, we could not show that patients benefited from chemotherapy. On contrary, there was a tendency that patients treated with chemotherapy had poorer overall survival. Further studies with larger sample sizes are needed to confirm this claim.
Citation Format: Huober J, Fasching PA, Taran F-A, Volz B, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Hartkopf AD, Lux MP, Lueftner D, Wallwiener M, Mueller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-11-07.
Collapse
Affiliation(s)
- J Huober
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - PA Fasching
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - F-A Taran
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - B Volz
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - F Overkamp
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - HC Kolberg
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - P Hadji
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - H Tesch
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - L Haeberle
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - J Ettl
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - AD Hartkopf
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - MP Lux
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - D Lueftner
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - M Wallwiener
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - V Mueller
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - MW Beckmann
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - E Belleville
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - P Wimberger
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - C Hielscher
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - M Geberth
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - N Fersis
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - W Abenhardt
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - C Kurbacher
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - R Wuerstlein
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - C Thomssen
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - M Untch
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - W Janni
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - D Wallwiener
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - SY Brucker
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - A Schneeweiss
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| | - TN Fehm
- Ulm University Hospital, Ulm, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Bavaria, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany
| |
Collapse
|
41
|
Szeto C, Benz S, Nguyen A, Rübner M, Wallwiener D, Tesch H, Hadji P, Fehm TN, Janni W, Overkamp F, Lueftner D, Lux MP, Wallwiener M, Beckmann MW, Huebner H, Ettl J, Hartkopf AD, Mueller V, Taran FA, Belleville E, Schneeweiss A, Soon-Shiong P, Rabizadeh S, Fasching PA. Abstract P1-07-20: Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-07-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Despite novel, targeted therapies, metastatic breast cancer patients have an extremely unfavourable prognosis. Prognostic and predictive factors for patients with advanced breast cancer are not well understood. Molecular assessment of the patient and the tumor in the metastatic situation is not routinely performed despite advances in molecular precision medicine indicating great benefit to this patient group. Here we present early findings from the first 142 patients of a prospective molecular breast cancer registry with completed transcriptomic profiling.
Methods: The PRAEGNANT study proctocol (NCT02338767) is a molecular registry designed to provide an infrastructure for the real-time comprehensive analysis of tumor and patient molecular characteristics under study conditions. Formalin fixed paraffin embedded tumors have been used from this registry to identify molecular, transcriptomic predictors for overall survival (OS).
Known clinical correlates for OS (e.g. hormone-receptor status, age at diagnosis, and BMI) were analyzed by Cox proportional hazard ratios, and compared to transcriptomic markers of outcomes. Transcriptomes for all patient tumors were sequenced on the Illumina sequencing platform, and analyzed by RSEM to estimate transcripts per million (TPM) values for each gene isoform. Log-TPM values were used in established (PAM50) and novel (hierarchical clustering) expression-based subtyping of tumor samples. Expression-based subtypes were demonstrated to be strong prognostic indicators by Cox analysis. A Lasso regression machine learning algorithm was used to develop an expression-based predictive model of OS.
Results: Hormone receptor positivity (HR=0.7, p<0.006) and TNBC status (HR=1.4, p<0.01) were significantly associated with outcomes. PAM50 subtypes were also strong indicators of outcomes (e.g. Basal disease compared to Luminal-A subtype has HR=1.4, p<0.017). A novel expression-based high-risk cluster in this cohort was more indicative of poor prognosis than clinical variates or Basal-type, with a HR=2.7 (p<0.009) when compared to Luminal-A subtype. An expression-based survival prediction model achieved a concordance-index of 0.65 in an unseen validation cohort. Patients predicted as having the shortest survival times were in the high-risk cluster.
Conclusions: Here we demonstrate using molecular profiling to develop prognostic signatures that out-perform standard clinical correlates of poor outcomes, even in a small subset of the total cohort. As the PRAEGNANT cohort expands these prognostic tools will continue to improve and supplement physician knowledge to improve patient outcomes.
Citation Format: Szeto C, Benz S, Nguyen A, Rübner M, Wallwiener D, Tesch H, Hadji P, Fehm TN, Janni W, Overkamp F, Lueftner D, Lux MP, Wallwiener M, Beckmann MW, Huebner H, Ettl J, Hartkopf AD, Mueller V, Taran FA, Belleville E, Schneeweiss A, Soon-Shiong P, Rabizadeh S, Fasching PA. Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-20.
Collapse
Affiliation(s)
- C Szeto
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - S Benz
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - A Nguyen
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - M Rübner
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - D Wallwiener
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - H Tesch
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - P Hadji
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - TN Fehm
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - W Janni
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - F Overkamp
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - D Lueftner
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - MP Lux
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - M Wallwiener
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - MW Beckmann
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - H Huebner
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - J Ettl
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - AD Hartkopf
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - V Mueller
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - FA Taran
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - E Belleville
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - A Schneeweiss
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - P Soon-Shiong
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - S Rabizadeh
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| | - PA Fasching
- NantOmics, LLC, Santa Cruz, CA; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Erlangen-Nuremberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Northwest Hospital, Frankfurt, Germany; University Hospital Duesseldorf, Düsseldorf, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; NantWorks, LLC, Culver City, CA
| |
Collapse
|
42
|
Romashova T, Polasik A, Friedl TWP, Rack B, Tzschaschel M, Fasching PA, Taran FA, Hartkopf A, Schneeweiss A, Mueller V, Bahriye A, Pantel K, Meier-Stiegen F, Wimberger P, Janni W, Fehm T, Huober J. Abstract OT1-03-05: The DETECT V-Study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot1-03-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Metastatic breast cancer (MBC) is usually an incurable disease and maintenance of quality of life (QoL) is one of the main aims of therapy. In patients with HER2-positive MBC taxane-based chemotherapy in combination with dual HER2 targeted therapy with trastuzumab and pertuzumab, has shown significantly increased progression free survival and overall survival. Adverse events are well-known side effects of any cytostatic treatment and can seriously impact the patients' QoL.
The synergistic combination of dual HER2-targeted therapy with trastuzumab and pertuzumab plus endocrine therapy might offer a better treatment option for these patients. Preclinical data and first clinical trial results suggest an additional benefit when a CDK4/6 inhibitor is added to the combination of endocrine therapy and anti HER2 treatment. DETECT V is a randomized phase III study comparing the safety and efficacy of trastuzumab plus pertuzumab in combination with either endocrine therapy or chemotherapy. In both treatment arms the CDK4/6 inhibitor ribociclib will be added.
Trial design and eligibility criteria: Patients are 1:1 randomized to receive dual HER2-targeted therapy with trastuzumab and pertuzumab combined with endocrine therapy and ribociclib or to chemotherapy with trastuzumab and pertuzumab followed by maintenance therapy with trastuzumab, pertuzumab, endocrine therapy and ribociclib when chemotherapy has stopped.
The sample size calculations are based on the assumption that the probability of having an adverse event as defined by the modified adverse event score for patients with HER2 positive metastatic breast cancer in the chemotherapy arm is 86.3%. Based on this assumption, a minimum of 121 patients per treatment arm is required to detect a 25% decreased risk of having an adverse event as defined by the modified adverse event score (i.e. a relative risk ratio of 0.75) for patients treated with dual HER2-targeted plus endocrine therapy and ribociclib as compared to patients treated with dual HER2-targeted plus chemotherapy with the combination of endocrine therapy and ribociclib as maintenance treatment (90% power, two-sided test, α = 0.05).
Specific aims: The primary objective of this study is to assess the tolerability of both treatment strategies, as assessed by the occurrence of AEs during the treatment period. Modified adverse event score was developed in order to better reflect the clinical, physiological and psychological impact of AEs on patients' QoL. Key secondary endpoint, besides the efficacy endpoints progression free survival (PFS) and overall survival, is to compare quality-adjusted survival (QAS), as measured using the quality-adjusted time without symptoms and toxicity (Q-TWiST) method, between both treatment arms.
The DETECT V trial comes along with a comprehensive translational program focusing on detection and phenotyping of circulating tumor cell (CTC)-and the assessment of marker expression on CTCs in order to calculate an endocrine responsiveness score.
Citation Format: Romashova T, Polasik A, Friedl TWP, Rack B, Tzschaschel M, Fasching PA, Taran F-A, Hartkopf A, Schneeweiss A, Mueller V, Bahriye A, Pantel K, Meier-Stiegen F, Wimberger P, Janni W, Fehm T, Huober J. The DETECT V-Study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT1-03-05.
Collapse
Affiliation(s)
- T Romashova
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - A Polasik
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - TWP Friedl
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - B Rack
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - M Tzschaschel
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - PA Fasching
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - F-A Taran
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - A Hartkopf
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - A Schneeweiss
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - V Mueller
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - A Bahriye
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - K Pantel
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - F Meier-Stiegen
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - P Wimberger
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - W Janni
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - T Fehm
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| | - J Huober
- University of Ulm, Ulm, Germany; Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany; Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, University Hospital Essen, Essen, Germany; University Hospital Hamburg-Eppendorf, Hamburg, Germany; Gynecology and Obstetrics, Heinrich-Heine University Hospital Duesseldorf, Duesseldorf, Germany; Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany
| |
Collapse
|
43
|
Janni WJ, Harbeck N, Rack B, Gluz O, Schneeweiss A, Kates R, Fehm T, Kreipe H, Kümmel S, Würstlein R, Hartkopf A, Clemens M, Reimer T, Friedl T, Häberle L, Fasching P, Nitz U. Abstract P6-13-01: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- WJ Janni
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - N Harbeck
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - B Rack
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - O Gluz
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - A Schneeweiss
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - R Kates
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - T Fehm
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - H Kreipe
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - S Kümmel
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - R Würstlein
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - A Hartkopf
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - M Clemens
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - T Reimer
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - T Friedl
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - L Häberle
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - P Fasching
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| | - U Nitz
- Universitätsfrauenklinik, Ulm, Germany; Universitätsfrauenklinik, Munich, Germany; Evangelisches Krankenhaus Bethesda Brustzentrum, Mönchengladbach, Germany; Universitätsfrauenklinik, Heidelberg, Germany; Women Study Group, Mönchengladbach, Germany; Universitätsfrauenklinik, Düsseldorf, Germany; Universitätsklinikum, Hannover, Germany; Brustzentrum Essen-Mitte, Essen, Germany; Universitätsfrauenklinik, Tübingen, Germany; Mutterhaus, Trier, Germany; Universitätsfrauenklinik, Rostock, Germany; Universitätsfrauenklinik, Erlangen, Germany
| |
Collapse
|
44
|
Taran FA, Fasching PA, Volz B, Huober J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Lux MP, Hartkopf AD, Lueftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A. Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Breast Cancer registries can help to understand how patient groups are treated outside clinical trials and what outcome is to expected for specific patient groups and therapy lines, which are not included into clinical trials. Here we present overall survival data according to therapy lines, patient and tumor characteristics.
Methods
The PRAEGNANT metastatic breast cancer registry (NCT02338167) is a prospective registry for breast cancer patients with focus on molecular biomarkers. Patients of all therapy lines with any kind of treatment are eligible for this registry. Collected data comprises therapies, adverse events, quality of life and other patient reported outcomes. Here we report on the comparison of overall survival data for different patient groups. For that analysis was restricted to patients included in the first therapy line for subgroup comparisons. Only for the analysis of the effect of therapy line on overall survival the complete dataset was used.
Results
A total of 1854 patients took part in this analysis. Of those 1016 were included first line, and 340, 213 and 285 patients 2nd line, 3rd lin4 and 4th line or higher respectively. A total of 339 deaths were observed. Two year survival rates (2Y-OS) for these groups were 75%, 65%, 57% and 36% (p(log-rank)<0.001). All further analyses were done only for the subset of first line treated patients with a total of 127 events. HER2 positive patients had the highest 2Y-OS rate of 84% and TNBC had the worst with 60% (see figure 1). Absolute numbers of deaths for TNBC, luminal A like, luminal B like and HER2 posives were 21, 48, 25, and 21. According to metastastic pattern the following survival rates were seen: brain (48%), other locations (69%), visceral (78%) and bone only (81%). ECOG was another factor that had a large influence on OS with ECOG 0: 83%, ECOG 1: 67% and EGOG 2+: 63% 2Y-OS. Age, BMI, number of concomitant diseases, and primary metastatic status did not have an influence on 2Y-OS.
Conclusion
This breast registry included patients over all therapy lines however mainly during the 1st line of therapy. Simple patient and tumor characteristics can classify patients into patients with differently favourable prognosis. Patients with HER2 positive disease had the best overall survival, while TNBC and luminal B like patients had the worst prognosis. As most of the patients were luminal A like 43% of all deaths occured within the group of luminal A like patients, which will need further focus for therapy development in the future.
Citation Format: Taran F-A, Fasching PA, Volz B, Huober J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Haeberle L, Ettl J, Lux MP, Hartkopf AD, Lueftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A. Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-09.
Collapse
Affiliation(s)
- F-A Taran
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - PA Fasching
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - B Volz
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - J Huober
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - F Overkamp
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - HC Kolberg
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - P Hadji
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - H Tesch
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - L Haeberle
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - J Ettl
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - MP Lux
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - AD Hartkopf
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - D Lueftner
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - M Wallwiener
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - V Müller
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - MW Beckmann
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - E Belleville
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - P Wimberger
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - C Hielscher
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - M Geberth
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - N Fersis
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - W Abenhardt
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - C Kurbacher
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - R Wuerstlein
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - C Thomssen
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - M Untch
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - W Janni
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - TN Fehm
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - D Wallwiener
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - SY Brucker
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| | - A Schneeweiss
- University of Tuebingen, Tuebingen, Germany; Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Ulm University Hospital, Ulm, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Northwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Biostatistics Unit, University Hospital Erlangen, Erlangen, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital, Berlin, Campus Benjamin Franklin, Berlin, Germany; University of Heidelberg, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamburg, Germany; ClinSol Gmbh & Co KG, Wuerzburg, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany; Klinik Hohe Warte, Bayreuth, Germany; MVZ Onk
| |
Collapse
|
45
|
Wallwiener M, Nabieva N, Haeberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Lueftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm T, Brucker SY, Wallwiener D, Schneeweiss A, Mueller V. Abstract P6-11-10: Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-11-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Improved progression-free survival is considered as treatment goal for patients with metastatic breast cancer (MBC) since it is assumed to delay or prevent deterioration of quality of life.Aim of our analysis was to examine the influence of disease progression on health-related quality of life (HRQoL).
Methods: The PRAEGNANT study comprises a real-life registry for patients with MBC. HRQoL was assessed with the EORTC-QLQ-C30 Version 3.0 questionnaire at study entry and every 3 months thereafter. The primary endpoint was minimally important deterioration (MID) in global HRQoL score by ≥ five points between baseline and any follow-up assessment. A logistic regression model was built with MID (yes/no) at a follow-up timepoint as outcome variable and several covariates as predictors.
Results: In total, 329 patients were included in this analysis, with disease progression in 63 patients. Concerning the primary study aim, progression status predicted MID of global HRQoL status in addition to the other covariates. The adjusted odds ratio for the effect of progression status on MID was 2.22 (95% CI: 1.04 – 4.73). Comparisons of mean differences of QoL domains/scales yielded no differences.
Conclusions: We provide evidence that disease progression in patients with metastatic breast cancer in a real-world registry has a significant negative impact on HRQoL as measured by MID of HRQoL. This study emphasizes the relevance of avoiding progression and prolonging PFS to maintain QoL.
Citation Format: Wallwiener M, Nabieva N, Haeberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg H-C, Hadji P, Tesch H, Ettl J, Lux MP, Lueftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm T, Brucker SY, Wallwiener D, Schneeweiss A, Mueller V. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-11-10.
Collapse
Affiliation(s)
- M Wallwiener
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - N Nabieva
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - L Haeberle
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - FA Taran
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - AD Hartkopf
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - B Volz
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - F Overkamp
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - AL Brandl
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - H-C Kolberg
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - P Hadji
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - H Tesch
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - J Ettl
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - MP Lux
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - D Lueftner
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - E Belleville
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - PA Fasching
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - W Janni
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - MW Beckmann
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - P Wimberger
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - C Hielscher
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - T Fehm
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - SY Brucker
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - D Wallwiener
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - A Schneeweiss
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| | - V Mueller
- University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Heidelberg, Baden-Wuerttemberg, Germany; University Hospital Erlangen, Erlangen, Germany; University of Heidelberg, Heidelberg, Germany; University of Tuebingen, Tuebingen, Germany; Oncologianova GmbH, Recklinghausen, Germany; Marienhospital Bottrop, Bottrop, Germany; Nordwest Hospital, Frankfurt, Germany; Oncology Practice at Bethanien Hospital, Frankfurt, Germany; Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany; Clin-Sol GmbH Wuerzburg, Wuerzburg, Germany; University Hospital Ulm, Ulm, Germany; University Hospital Dresden, TU Dresden, Dresden, Germany; gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany; Heinrich Heine University of Dusseldorf, Dusseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Hamburg-Eppendorf University Medical Center, Hamb
| |
Collapse
|
46
|
Walter VP, Taran FA, Wallwiener M, Brucker SY, Hartkopf AD. Abstract P1-01-16: Detection of disseminated tumor cells in DCIS patients impacts local recurrence. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-01-16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Recently it was shown that tumor cell dissemination is an early event in breast cancer progression (Hosseini et al., Nature 2016). This has been backed up by an assessment of over 100,000 patients with in situ carcinoma (DCIS), where some patients developed distant metastases and died from breast cancer without presenting with local invasive recurrence (Narod et al., JAMA Oncology 2015). We therefore analyzed the presence and clinical impact of disseminated tumor cells (DTC) in the bone marrow (BM) of DCIS patients.
Methods
BM aspirates were collected from patients undergoing surgery for primary DCIS at Tuebingen University Hospital between 2001 and 2016. Exclusion criteria were presence of invasive breast cancer, bilateral or metastatic disease as well as other malignancies in their history. DTC were identified by immunocytochemistry using the A45-B/B3 anti-pancytokeratin antibody.
Results
627 patients were included. Median follow-up was 49 months. 72 (11%) had detectable DTC. The detection of DTC was not significantly associated with lymph node positivity (3/479, Fisher's exact test: p=0.307) or tumor size (median 30mm, Wilcoxon test: p=0.952).
In 33 (5%) women, a disease recurrence was observed. Of 31 local recurrences 19 were invasive. 7 Patients developed distant metastases, four without an invasive recurrence beforehand. 14 patients died during follow-up.
The detection of at least 2 DTC per 1.5x106 mononuclear BM cells was significantly associated with a lower local recurrence free survival (log-rank: p=0.023) whereas there was no significant difference in distant disease free survival (p=0.315) and overall survival (p=0.083).
Discussion
For the first time, we were able to show that DTC-detection in DCIS patients is associated with local recurrence.
The number of distant metastases in women without invasive local recurrence detected in this cohort was comparable to earlier findings at different centers. This study warrants further investigations concerning evolutionary relationship between primary tumor, minimal residual disease, local recurrence and clinically detectable macrometastases.
Citation Format: Walter VP, Taran F-A, Wallwiener M, Brucker SY, Hartkopf AD. Detection of disseminated tumor cells in DCIS patients impacts local recurrence [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-01-16.
Collapse
Affiliation(s)
- VP Walter
- University of Tuebingen; University of Heidelberg
| | - F-A Taran
- University of Tuebingen; University of Heidelberg
| | - M Wallwiener
- University of Tuebingen; University of Heidelberg
| | - SY Brucker
- University of Tuebingen; University of Heidelberg
| | - AD Hartkopf
- University of Tuebingen; University of Heidelberg
| |
Collapse
|
47
|
Hilke F, Schroeder C, Doehring A, Faust U, Forschner A, Hartkopf A, Schittenhelm M, Brecht I, Hendrick J, Riess O. Genetic panel sequencing for advanced stage cancer disease in the clinic. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx511.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Andress J, Sandru M, Taran FA, Kommoss S, Wallwiener M, Brucker SY, Hartkopf AD. Detektion von disseminierten Tumorzellen im Knochenmark von Patientinnen mit Borderlinetumoren des Ovars. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1606172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- J Andress
- Department für Frauengesundheit, Universitätsklinikum Tübingen
| | - M Sandru
- Department für Frauengesundheit, Universitätsklinikum Tübingen
| | - FA Taran
- Department für Frauengesundheit, Universitätsklinikum Tübingen
| | - S Kommoss
- Department für Frauengesundheit, Universitätsklinikum Tübingen
| | | | - SY Brucker
- Department für Frauengesundheit, Universitätsklinikum Tübingen
| | - AD Hartkopf
- Department für Frauengesundheit, Universitätsklinikum Tübingen
| |
Collapse
|
49
|
Pasternak J, Wenz S, Taran FA, Krämer B, Hartkopf AD, Greif K, Wallwiener D, Fend F, Brucker SY, Staebler A, Kommoss S. Positive L1CAM immunohistochemistry in benign endometrial changes – potential pitfall in endometrial carcinoma pathology. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1606169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- J Pasternak
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen
| | - S Wenz
- Institut für Pathologie, Universitätsklinikum Tübingen, Tübingen
| | - FA Taran
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen
| | - B Krämer
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen
| | - AD Hartkopf
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen
| | - K Greif
- Institut für Pathologie, Universitätsklinikum Tübingen, Tübingen
| | - D Wallwiener
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen
| | - F Fend
- Institut für Pathologie, Universitätsklinikum Tübingen, Tübingen
| | - SY Brucker
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen
| | - A Staebler
- Institut für Pathologie, Universitätsklinikum Tübingen, Tübingen
| | - S Kommoss
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen
| |
Collapse
|
50
|
Deutsch TM, Riethdorf S, Stefanovic S, Hartkopf AD, Taran FA, Trumpp A, Brucker SY, Schütz F, Pantel K, Schneeweiss A, Wallwiener M. Zirkulierende Tumorzellen zur individuellen Therapiekontrolle beim metastasierten Mammakarzinom. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1606227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- TM Deutsch
- Universitäts-Frauenklinik Heidelberg, Heidelberg
- Nationales Centrum für Tumoerkrankungen (NCT), Heidelberg, Heidelberg
| | - S Riethdorf
- Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - S Stefanovic
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - AD Hartkopf
- Universitäts-Frauenklinik Tübingen, Tübingen
| | - FA Taran
- Universitäts-Frauenklinik Tübingen, Tübingen
| | - A Trumpp
- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
| | - SY Brucker
- Universitäts-Frauenklinik Tübingen, Tübingen
| | - F Schütz
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| | - K Pantel
- Nationales Centrum für Tumoerkrankungen (NCT), Heidelberg, Heidelberg
| | - A Schneeweiss
- Nationales Centrum für Tumoerkrankungen (NCT), Heidelberg, Heidelberg
| | - M Wallwiener
- Universitäts-Frauenklinik Heidelberg, Heidelberg
| |
Collapse
|